Cite
MLA Citation
F Badibouidi et al.. “4CPS-072 Comparison of immune checkpoint inhibitors (nivolumab, pembrolizumab, atézolizumab and durvalumab) in the treatment of non-small cell lung cancer: tolerance and financial impact.” European journal of hospital pharmacy, vol. 27, n.d., p. A81. http://access.bl.uk/ark:/81055/vdc_100137792709.0x000004